- 11/27/2018
- 25 Students from China Medical University Win Eisai China Scholarships and Grants
- 11/22/2018
- EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 72ND AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
- 11/12/2018
- EISAI LAUNCHES LENVIMA® (LENVATINIB) IN CHINA
- 11/07/2018
- EISAI CHINA COMMENCES FULL-SCALE OPERATION OF NEW SUZHOU PLANT
- 10/27/2018
- Eisai China Inc. Held the "2018 ADS"
- 10/26/2018
- EISAI PRESENTS NEW DATA ON LEMBOREXANT FOR TREATMENT OF IRREGULAR SLEEP-WAKE RHYTHM DISORDER IN PATIENTS WITH ALZHEIMER’S DISEASE AT THE 11TH CLINICAL TRIALS IN ALZHEIMER’S DISEASE CONFERENCE
- 10/25/2018
- EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
- 10/23/2018
- Eisai China Donates Approximately RMB2.5 Million Yuan Worth of Medicines to the “Health to Countryside” Project for Five Consecutive Years
- 10/18/2018
- EISAI TO PRESENT LATEST DATA ON ALZHEIMER’S DISEASE / DEMENTIA PIPELINE AT 11TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE
- 10/17/2018
- Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
